Information Provided By:
Fly News Breaks for February 11, 2020
Feb 11, 2020 | 07:14 EDT
Goldman Sachs analyst Salveen Richter raised his price target for Seattle Genetics to $165 from $126 saying he continues to see an "attractive setup" despite the stock's recent outperformance. The attractive setup is on three fronts: revenue execution with three to four launches and achievable guidance, pipeline progress, and M&A optionality, Richter tells investors in a research note. The analyst maintains a Buy rating on the shares.
News For SGEN From the Last 2 Days
There are no results for your query SGEN